Cargando…
Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis
African Americans (AAs) and obese individuals have increased thrombotic risk. This study evaluated the effectiveness and safety of rivaroxaban versus warfarin in obese, AAs with nonvalvular atrial fibrillation (NVAF) or venous thromboembolism (VTE). Optum® De-Identified Electronic Health Record (EHR...
Autores principales: | Costa, Olivia S., Beyer-Westendorf, Jan, Ashton, Veronica, Milentijevic, Dejan, Moore, Kenneth Todd, Bunz, Thomas J., Coleman, Craig I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588768/ https://www.ncbi.nlm.nih.gov/pubmed/33085526 http://dx.doi.org/10.1177/1076029620954910 |
Ejemplares similares
-
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for
Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018) -
Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis
por: Costa, Olivia S., et al.
Publicado: (2020) -
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
por: Martinez, Brandon K., et al.
Publicado: (2018) -
Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
por: Alberts, Mark, et al.
Publicado: (2020) -
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)